This clinical trial is focused on studying a liver condition called Non-alcoholic Steatohepatitis (NASH), which is a type of liver inflammation and damage caused by a buildup of fat in the liver. The study is testing a new treatment called efinopegdutide, also known by its code name MK-6024. This treatment is given as a solution for injection using a pre-filled syringe. The purpose of the study is to evaluate the effect of efinopegdutide compared to a placebo on the resolution of NASH without worsening liver fibrosis, which is the thickening and scarring of liver tissue, over a period of 52 weeks.
Participants in the study will receive either efinopegdutide or a placebo through subcutaneous injection, which means the injection is given under the skin. The study will last for about a year, during which the safety and tolerability of efinopegdutide will also be assessed. The main goal is to see if the treatment can help resolve NASH without making fibrosis worse. Additionally, the study will monitor any changes in body weight and any adverse events, which are unwanted effects that might occur during the study.
This trial is important for understanding how effective efinopegdutide is in treating NASH and ensuring it is safe for use. Participants will be closely monitored throughout the study to gather information on how well the treatment works and any side effects that may arise. The results of this study could provide valuable insights into new treatment options for people with NASH.
Austria 
Belgium 
Czechia 
France 
Hungary 
Italy 
Portugal 
Spain 
